Proactive Investors - Run By Investors For Investors

Unilever surfing a volatile world - Deutsche

Unilever surfing a volatile world - Deutsche
Love it, hate it - but Unilever results were good, says Deutsche

Deutsche has picked today to remind investors how good consumer goods giant Unilever (LON:ULVR) really is.

It rates the shares a 'buy' and pumps up the price target to 3,350p from 3,250p, saying the  stock is successfully surfing along in a volatile world, after full year results were...well,. 'good'.

As an example, Deutsche notes that it is easy to forget that at this time last year, the prospects for EMs (emerging markets) looked bleak, and within that context, Unilever had set itself the aim to grow somewhere between 2-4% like-for-like.

"It achieved 4.1% and through the course of the year, EM volumes growth has nearly tripled from c.1% to c.3%," notes analyst Harold Thompson.

Yesterday, the FTSE100 group, whose brands include Marmite, Pot Noodle, and Dove soap, said turnover in 2015 rose 10% to €53.3bn, while underlying operating profit lifted 12% to €7.9bn.

Also in brokerland midweek, challenger bank Aldermore (LON:ALD) gets a boost from Credit Suisse, which has upgraded the shares to 'outperform' from 'neutral'.

Meanwhile, analysts at Barclays have been shopping around and given online retailer Boohoo (LON:BOO) an upgrade to 'overweight' from 'equalweight'.

The target price moves to 45p from 34p after the firm's Christmas trading numbers.

Analyst Christodoulos Chaviaras said: "Positive sales momentum, more flexible/realistic margin targets, better clarity on capex plans and improved management communication combine to bring a noticeable improvement in Boohoo's investment thesis and mark steady progress in restoring investors' confidence."

The broker has raised growth estimates by 4% and is now 8% above Reuters consensus EPS in the next three years, it notes.

Also today, Barclays upgrades its general retail sector view to 'neutral' from 'negative'.

German heavyweight bank Berenberg has downgraded Quinetiq (LON:QQ.) to 'sell' from 'hold' and reduced the target price by 20p to 210p.

It produces a tome on the UK arerospace and defence market and says the firm is under pressure from forthcoming margin pressure, negative earnings growth of minus 3% for 2017 and 2018 estimates and 'anaemic' organic growth potential.

Principally, as a result of forthcoming single-source regulatory changes, we estimate an EBIT impact in FY 2017/18E of £3.3m/£9.0m respectively," it said.

In small caps, Summit Therapeutics (LON:SUMM) has been awarded a European patent for ridinilazole -  its new antibiotic for hospital superbug C.Difficile.

Broker N+1 Singer said it remained positive on the group’s future prospects following the news.

"Recurrent disease represents a key clinical issue with around 30% of patients at risk of recurrent disease after the initial episode. Ridinilazole met its primary objective in a Phase II trial in November, demonstrating a superior sustained clinical response to standard treatment. Summit is currently evaluating all options for progressing ridinilazole into Phase III trials and we look forward to an update in due course," said analyst Sheena Berry.

Giles_55af4ddca6481.jpg


No investment advice: The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use